The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for acute severe asthma

Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, Coats T
Record ID 32010000308
Authors' objectives: We aimed to determine whether i.v. or nebulised magnesium sulphate improves symptoms of breathlessness and reduces the need for hospital admission in adults with acute severe asthma.
Authors' recommendations: We were unable to demonstrate a clinically worthwhile benefit from magnesium sulphate in acute severe asthma. There was some weak evidence of an effect of i.v. magnesium sulphate on hospital admission, but no evidence of an effect on VAS breathlessness or PEFR compared with placebo. We found no evidence that nebulised magnesium sulphate was more effective than placebo.
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Acute Disease
  • Administration, Inhalation
  • Anti-Asthmatic Agents
  • Injections, Intravenous
  • Magnesium Sulfate
  • Nebulizers and Vaporizers
  • Randomized Controlled Trials as Topic
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:
Copyright: <p>2014 Queen's Printer and Controller of HMSO</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.